| Estimating the intake of moderation foods and evaluating associations with risk of cancer and mortality |
Kaelyn Burns |
National Cancer Institute |
PLCO |
May 4, 2026 |
PLCO-2045 |
| Reexamine trial outcomes in PLCO to identify interactions of screening effects with screen results and other covariates (Original Project: PLCO-1091) |
Hormuzd Katki |
American Cancer Society |
PLCO |
Apr 28, 2026 |
PLCO-2043 |
| Deep Learning to Improve Screening of Interstitial Lung Diseases |
Asif Abdul Hameed |
Henry Ford Health |
NLST |
Apr 28, 2026 |
NLST-1505 |
| Estimating the lung cancer mortality benefit of screening within lung cancer risk strata in the National Lung Screening Trial (Original Project: 201204-0017) |
Hormuzd Katki |
American Cancer Society |
NLST |
Apr 28, 2026 |
NLST-1507 |
| Association between microplastic exposure and risk of never-smoking lung cancer in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial |
Qing Lan |
National Cancer Institute |
PLCO |
Apr 21, 2026 |
2025-0048 |
| Generalizability of the PLCO |
Sarah Robertson |
Dartmouth College |
PLCO |
Apr 20, 2026 |
PLCO-2039 |
| Treatment-Conditioned World Models for Lung Cancer Progression Prediction Using Longitudinal Low-Dose CT Imaging |
Luca Pegolotti |
Nucleo Research, Inc. |
NLST |
Apr 20, 2026 |
NLST-1502 |
| Statistical methods to detect and estimate etiologic heterogeneity in epidemiologic studies |
Anil Chaturvedi |
National Cancer Institute |
PLCO |
Apr 13, 2026 |
PLCO-2038 |
| Developing an All-cancer Risk Model |
Paul Pinsky |
National Institutes of Health |
PLCO |
Apr 13, 2026 |
PLCO-2040 |
| Integrating Early Detection of Heart Disease with Lung Cancer Powered by AI-CXR |
Morteza Naghavi |
HeartLung Technologies |
NLST |
Mar 31, 2026 |
NLST-1501 |
| AI-Enabled Opportunistic Detection of Cardiovascular Disease Risk from Chest Radiographs in the PLCO Cohort |
Morteza Naghavi |
HeartLung Technologies |
PLCO |
Mar 30, 2026 |
PLCOI-2034 |
| Integrative Genomic, Histologic, and Spatial Profiling of ClonalHematopoiesis in Lung Cancer |
Janghee Woo |
Emory University |
PLCO |
Mar 30, 2026 |
PLCOI-2024 |
| Pilot study of circulating immune checkpoint proteins in persons with and without cancer |
Kara Michels |
Albert Einstein College of Medicine |
PLCO |
Mar 26, 2026 |
2026-9129 |
| Integrative Analysis of Metabolic Programs Associated with Cancer Risk and Outcomes in the PLCO Cohort |
Blake Rushing |
University of North Carolina at Chapel Hill |
PLCO |
Mar 26, 2026 |
PLCO-2035 |
| Identifying Early ILD using Quantitative CT (QCT) Thresholds |
Jennifer Wang |
University of Michigan |
NLST |
Mar 23, 2026 |
NLST-1499 |
| Validation of a bladder cancer risk model with lifestyle and environmental risk factors and polygenic risk score in two prospective cohorts. (PLCO-1972 continued) |
Parichoy Pal Choudhury |
American Cancer Society |
PLCO |
Mar 16, 2026 |
PLCO-2033 |
| Utilizing serial screening data to estimate dwell time of cancers and colorectal adenomas and develop new cancer stage progression models |
Joachim Worthington |
The University of Sydney |
PLCO |
Mar 16, 2026 |
PLCO-2032 |
| Modifiable lifestyle factors and aging |
Yikyung Park |
Washington University in St. Louis |
PLCO |
Mar 16, 2026 |
PLCO-2031 |
| Longitudinal Modelling of Prostate-Specific Antigen (PSA) Trajectories and Their Association with Prostate Cancer Diagnosis in the PLCO Trial |
Ciarán Courtney O'Toole |
University of Limerick |
PLCO |
Mar 16, 2026 |
PLCO-2025 |
| Lung cancer incidence following negative biopsy |
Paul Pinsky |
NCI |
NLST |
Mar 16, 2026 |
NLST-1498 |
